Sanofi: BMS completes acquisition of Mirati Therapeutics
(CercleFinance.com) - Last week, Bloomberg reported that Sanofi was considering the acquisition of oncology biotech Mirati Therapeutics.
This morning, we learned that Bristol Myers Squibb had completed the acquisition of the company for $4.8bn, i.e. $58 per share.
Mirati shareholders will also receive a non-negotiable conditional value right (CVR) for each Mirati share held, with a potential value of $12 per share, representing an additional value opportunity of $1bn.
Thanks to this acquisition, Bristol Myers Squibb will strengthen its portfolio with Krazati, a US FDA-approved non-small cell lung cancer drug, as well as several other promising clinical assets.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This morning, we learned that Bristol Myers Squibb had completed the acquisition of the company for $4.8bn, i.e. $58 per share.
Mirati shareholders will also receive a non-negotiable conditional value right (CVR) for each Mirati share held, with a potential value of $12 per share, representing an additional value opportunity of $1bn.
Thanks to this acquisition, Bristol Myers Squibb will strengthen its portfolio with Krazati, a US FDA-approved non-small cell lung cancer drug, as well as several other promising clinical assets.
Copyright (c) 2023 CercleFinance.com. All rights reserved.